@article{3bdcb97448a6468593770b796a44b78f,
title = "Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors",
abstract = "Melanoma is one of the deadliest forms of skin cancer. Although BRAF inhibitors significantly enhance survival of metastatic melanoma patients, most patients relapse after less than a year of treatment. We previously reported that mRNA binding protein Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is overexpressed in metastatic melanoma and that expression of IGF2BP1 confers resistance to chemotherapeutic agents. Here we demonstrate that IGF2BP1 plays an important role in the sensitivity of melanoma to targeted therapy. Inhibition of IGF2BP1 enhances the effects of BRAF-inhibitor and BRAF-MEK inhibitors in BRAFV600E melanoma. Also, knockdown of IGF2BP1 alone is sufficient to reduce tumorigenic characteristics in vemurafenib-resistant melanoma. These findings suggest that IGF2BP1 can be a novel therapeutic target for melanoma.",
author = "Kim, {Tae Won} and Thomas Havighurst and Kim, {Kyung Mann} and Mark Albertini and Xu, {Yaohui G.} and Spiegelman, {Vladimir S.}",
note = "Funding Information: This study was supported in part by the NIH grant R01 AR063361 (V.S.S.), Dermatology Foundation Career Development Award (Y.G.X.), University of Wisconsin-Madison Institute for Clinical & Translational Research Grant UL1TR000427/Skin Disease Research Center NIAMS grant P30 AR066524 (Y.G.X.), and NCI Cancer Center Support Grant P30 CA014520 (K.M.K.). The authors also want to thank Dr Vijay Setaluri for helpful discussion, and Megan L Maguire, and Diane Bock for their administrative support. Funding Information: Dermatology Foundation Career Development Award; University of Wisconsin-Madison Institute for Clinical & Translational Research Grant, Grant number: UL1TR000427; Skin Disease Research Center NIAMS, Grant number: P30 AR066524; NCI Cancer Center Support Grant, Grant number: P30 CA014520; NIH, Grant number: R01 AR063361 Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = may,
doi = "10.1002/mc.22786",
language = "English (US)",
volume = "57",
pages = "678--683",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "5",
}
